Synergy Innovation Co. Ltd - Asset Resilience Ratio
Synergy Innovation Co. Ltd (048870) has an Asset Resilience Ratio of 18.41% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Synergy Innovation Co. Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2024)
This chart shows how Synergy Innovation Co. Ltd's Asset Resilience Ratio has changed over time. See 048870 net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Synergy Innovation Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Synergy Innovation Co. Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩61.74 Billion | 18.41% |
| Total Liquid Assets | ₩61.74 Billion | 18.41% |
Asset Resilience Insights
- Good Liquidity Position: Synergy Innovation Co. Ltd maintains a healthy 18.41% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Synergy Innovation Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Synergy Innovation Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Synergy Innovation Co. Ltd (2006–2024)
The table below shows the annual Asset Resilience Ratio data for Synergy Innovation Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.16% | ₩35.05 Billion ≈ $23.75 Million |
₩314.06 Billion ≈ $212.83 Million |
-3.77pp |
| 2023-12-31 | 14.93% | ₩42.69 Billion ≈ $28.93 Million |
₩285.90 Billion ≈ $193.75 Million |
+13.77pp |
| 2022-12-31 | 1.16% | ₩2.64 Billion ≈ $1.79 Million |
₩227.38 Billion ≈ $154.09 Million |
-15.05pp |
| 2021-12-31 | 16.21% | ₩32.85 Billion ≈ $22.26 Million |
₩202.70 Billion ≈ $137.37 Million |
-0.47pp |
| 2020-12-31 | 16.68% | ₩26.40 Billion ≈ $17.89 Million |
₩158.31 Billion ≈ $107.29 Million |
+7.04pp |
| 2019-12-31 | 9.64% | ₩14.20 Billion ≈ $9.62 Million |
₩147.29 Billion ≈ $99.82 Million |
-12.96pp |
| 2018-12-31 | 22.60% | ₩27.57 Billion ≈ $18.69 Million |
₩122.01 Billion ≈ $82.68 Million |
+15.07pp |
| 2017-12-31 | 7.53% | ₩7.98 Billion ≈ $5.41 Million |
₩106.06 Billion ≈ $71.87 Million |
-2.99pp |
| 2016-12-31 | 10.52% | ₩6.27 Billion ≈ $4.25 Million |
₩59.67 Billion ≈ $40.44 Million |
+6.68pp |
| 2015-12-31 | 3.83% | ₩616.99 Million ≈ $418.12K |
₩16.10 Billion ≈ $10.91 Million |
-16.76pp |
| 2014-12-31 | 20.59% | ₩16.90 Billion ≈ $11.45 Million |
₩82.08 Billion ≈ $55.62 Million |
+3.10pp |
| 2013-12-31 | 17.49% | ₩16.89 Billion ≈ $11.44 Million |
₩96.56 Billion ≈ $65.44 Million |
+5.28pp |
| 2012-12-31 | 12.21% | ₩15.90 Billion ≈ $10.77 Million |
₩130.20 Billion ≈ $88.24 Million |
-11.71pp |
| 2011-12-31 | 23.92% | ₩30.15 Billion ≈ $20.43 Million |
₩126.03 Billion ≈ $85.41 Million |
+1.75pp |
| 2009-12-31 | 22.17% | ₩31.70 Billion ≈ $21.48 Million |
₩143.00 Billion ≈ $96.91 Million |
-25.34pp |
| 2008-12-31 | 47.51% | ₩85.27 Billion ≈ $57.78 Million |
₩179.47 Billion ≈ $121.63 Million |
-2.02pp |
| 2007-12-31 | 49.53% | ₩77.56 Billion ≈ $52.56 Million |
₩156.60 Billion ≈ $106.13 Million |
+24.85pp |
| 2006-12-31 | 24.67% | ₩33.75 Billion ≈ $22.87 Million |
₩136.78 Billion ≈ $92.69 Million |
-- |
About Synergy Innovation Co. Ltd
Synergy Innovation Co., Ltd. engages in the research and development, and investment of generic and new drugs, medical devices, and health functional foods in South Korea. It produces and sells various culture media for hospitals, pharmaceuticals, and food/cosmetics; manufactures synergy innovation " universal transport solutions (SI-UTS); and invests and develops in various fields comprising mic… Read more